Search results for "FEM"

showing 10 items of 28965 documents

CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure

2021

Abstract Background Intrarenal venous flow (IRVF) measured by Doppler ultrasound has gained interest as a potential surrogate marker of renal congestion and adverse outcomes in heart failure. In this work, we aimed to determine if antigen carbohydrate 125 (CA125) and plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) are associated with congestive IRVF patterns (i.e., biphasic and monophasic) in acute heart failure (AHF). Methods and results We prospectively enrolled a consecutive cohort of 70 patients hospitalized for AHF. Renal Doppler ultrasound was assessed within the first 24-h of hospital admission. The mean age of the sample was 73.5 ± 12.3 years; 47.1% were female, and…

medicine.medical_specialtymedicine.drug_classCarbohydrates030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineVenous flow03 medical and health sciencesCA1250302 clinical medicineInterquartile rangeIntrarrenal Doppler ultrasoundInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumans030212 general & internal medicineHeart FailureOriginal Scientific PaperSurrogate endpointbusiness.industryCardiorenalMembrane ProteinsAcute heart failureGeneral Medicinemedicine.diseasePrognosisPeptide FragmentsROC CurveHeart failureCA-125 AntigenCohortNTproBNPCardiologyCongestionFemaleDoppler ultrasoundCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionBiomarkers
researchProduct

Endothelin action on goat cerebral arteries.

1990

Abstract Cumulative application of endothelin-1 (human) markedly constricted goat isolated cerebral arteries in a concentration-dependent manner. Contractile responses were not affected by removal of endothelial cells. Removal of extracellular calcium or addition of the calcium channel blocker nicardipine (10−7 M) failed to abolish responses to endothelin. The results suggest that the endothelium-independent constriction of cerebral arteries produced by endothelin cannot be explained solely by voltage-dependent calcium channels. The contractile responses are likely to be mediated by stimulation of specific receptors for this peptide.

medicine.medical_specialtymedicine.drug_classCerebral arteriesNicardipinePharmaceutical Sciencechemistry.chemical_elementStimulationCalcium channel blockerBiologyCalciumIn Vitro TechniquesMuscle Smooth VascularNicardipineInternal medicinemedicineAnimalsPharmacologyVoltage-dependent calcium channelEndothelinsGoatsCerebral ArteriesEndocrinologymedicine.anatomical_structurechemistrycardiovascular systemCalciumFemaleEndothelium VascularEndothelin receptormedicine.drugBlood vesselMuscle ContractionThe Journal of pharmacy and pharmacology
researchProduct

Relationships Between Biochemical Markers of Hyperandrogenism and Metabolic Parameters in Women with Polycystic Ovary Syndrome: A Systematic Review a…

2019

AbstractWhile several studies have documented an increased risk of metabolic disorders in patients with polycystic ovary syndrome (PCOS), associations between androgenic and metabolic parameters in these patients are unclear. We aimed to investigate the relationships between biochemical markers of hyperandrogenism (HA) and metabolic parameters in women with PCOS. In this systematic review and meta-analysis, a literature search was performed in the PubMed, Scopus, Google Scholar, ScienceDirect, and Web of Science from 2000 to 2018 for assessing androgenic and metabolic parameters in PCOS patients. To assess the relationships between androgenic and metabolic parameters, meta-regression analys…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryBlood Pressure030209 endocrinology & metabolism030204 cardiovascular system & hematologyBiochemistryFerriman–Gallwey score03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyDehydroepiandrosterone sulfateInsulin resistanceInternal medicinemedicineHumansInsulinTestosteronebusiness.industryBiochemistry (medical)Metabolic disorderHyperandrogenismConfoundingGeneral Medicinemedicine.diseaseAndrogenPolycystic ovaryCholesterolEndocrinologychemistryAndrogensFemaleHyperandrogenismbusinessPolycystic Ovary SyndromeHormone and Metabolic Research
researchProduct

Increased 2-Hydroxylation of Estrogen in Women with a Family History of Osteoporosis

2005

Recent studies indicate that women with predominant estrogen metabolism through the 2-hydroxyl (inactive) pathway have lower bone mineral density (BMD) compared with those with predominant 16alpha-hydroxylation (active). Although many factors have been identified to affect estrogen metabolism, the role of a family history of osteoporosis remains unknown. The objective of this study was to investigate the influence of family history of osteoporosis and other clinical factors on estrogen hydroxylation. This was a cross-sectional study conducted in a university-based research center from May 2002 to February 2004. The participants included 175 otherwise healthy postmenopausal women at least 1 …

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismUrinary systemClinical BiochemistryOsteoporosisHydroxylationBiochemistryArticleHydroxylationchemistry.chemical_compoundEndocrinologyBone DensityInternal medicinemedicineHumansosteoporosiFemurFamily historyAgedBone mineralPostmenopausal womenbusiness.industryBiochemistry (medical)EstrogensMiddle Agedmedicine.diseaseEstrogenCross-Sectional StudiesEndocrinologychemistryEstrogenOsteoporosiswomen health.CalciumFemalebusinessThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.

2018

OBJECTIVE To determine the current state of knowledge and provide evidence-based recommendations that could be valid for all specialists taking care of female pattern hair loss (FPHL), a common form of hair loss in women that is characterized by the reduction of hair density in the central area of the scalp, whereas the frontal hairline is generally well conserved. PARTICIPANTS An expert task force appointed by the Androgen Excess and PCOS Society, which included specialists from dermatology, endocrinology, and reproductive endocrinology. DESIGN Levels of evidence were assessed and graded from A to D. Peer-reviewed studies evaluating FPHL published through December 2017 were reviewed. Crite…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismVasodilator AgentsClinical BiochemistryReproductive EndocrinologySpironolactoneAndrogen ExcessBiochemistry030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineEndocrinology5-alpha Reductase InhibitorsInternal medicinemedicineVitamin D and neurologyHumansLow-Level Light TherapyMineralocorticoid Receptor Antagonists030219 obstetrics & reproductive medicineScalpintegumentary systembusiness.industryPlatelet-Rich PlasmaBiochemistry (medical)HyperandrogenismAlopeciaAndrogen Antagonistsmedicine.diseaseAndrogenDermatologymedicine.anatomical_structureEndocrinologyHair lossMinoxidilScalpMinoxidilFemalebusinessHyperandrogenismmedicine.drugPolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct

Effects of indomethacin on muscarinic inhibition of endogenous noradrenaline release from rat isolated trachea

1993

The release of endogenous noradrenaline from rat isolated tracheae was evoked by electrical field stimulation (3 Hz, 540 pulses) in the presence of yohimbine, desipramine and tyrosine. The muscarine receptor agonist oxotremorine concentration-dependently inhibited the evoked release of noradrenaline by 95% at 1 μmol/l, EC50 values in two series of experiments 41 and 57 nmol/l, respectively. The effect of oxotremorine was antagonized by the non-selective muscarine receptor antagonist scopolamine (10–1000 nmol/l) in a manner suggesting a simple competitive interaction (slope of Schild plot −0.94; pA2 value 8.88). However, the M2 selective muscarine receptor antagonist methoctramine (0.1–10 μm…

medicine.medical_specialtymedicine.drug_classIndomethacinDiaminesIn Vitro TechniquesRats Sprague-DawleyNorepinephrinechemistry.chemical_compoundInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineMethoctramineAnimalsPharmacologyMuscarineOxotremorineGeneral MedicineMuscarinic acetylcholine receptor M1Receptor antagonistReceptors MuscarinicPirenzepineRatsTracheaSchild regressionEndocrinologychemistryProstaglandinsFemalemedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Protrhombotic Effects of Contraceptives

2010

The use of oral contraceptives first became widespread some 40 years ago, and reports of an excess risk of cardiovascular disease among women who used these agents soon followed. Few drugs have been the object of such intensive epidemiological research, the outcome of which has provided clinicians with detailed information about risks not only of specific thrombotic diseases but also important non-contraceptive benefits from the pill. Recently, oral contraceptives have been classified by some according to "generation" (first, second, third, and most recently, fourth generation): first-generation formulations containing lynestrenol or norethindrone, second-generation formulations containing …

medicine.medical_specialtymedicine.drug_classLipid Metabolism DisordersMyocardial InfarctionPhysiologyGestodeneRisk AssessmentRisk FactorsDesogestrelInternal medicineDrug DiscoverymedicineHumansLevonorgestrelGlucose Metabolism DisordersVenous ThrombosisPharmacologyHemostasisbusiness.industryModels CardiovascularAtherosclerosisLipid MetabolismNorgestimateSettore MED/11 - Malattie Dell'Apparato CardiovascolareLynestrenolEndocrinologyEstrogenPillHypertensionFemaleRisk assessmentbusinessTrhombosis contraceptivesContraceptives Oralmedicine.drugCurrent Pharmaceutical Design
researchProduct

Blood Coagulation and Thrombosis in Patients with Ovarian Malignancy

1997

SummaryOvarian cancer cells appear to be capable of both thrombin formation and induction of fibrin degradation which may be essential prerequisites for the development of deep vein thrombosis (DVT) as well as the spread of malignancy. To study further this coagulation – cancer interaction in 60 patients with untreated ovarian cancer of FIGO stage I-IV the incidence of DVT was recorded pre-operatively, postoperatively on day 1, 3, 5, 7, 10, before each of six cycles of Cisplati- num/Epirubicin/Cyclophosphamide chemotherapy, during follow-up and in the post-operative period of second look surgery. In addition, blood coagulation tests results were determined prospectively. Two patients were e…

medicine.medical_specialtymedicine.drug_classLow molecular weight heparinGastroenterologyPostoperative ComplicationsMedian follow-upThromboembolismInternal medicinemedicineHumansProspective Studiescardiovascular diseasesBlood CoagulationAgedBlood coagulation testOvarian NeoplasmsUnivariate analysisHeparinbusiness.industryAntithrombinAnticoagulantAnticoagulantsHematologyHeparinHeparin Low-Molecular-WeightMiddle AgedSurvival AnalysisSurgeryFemaleBlood Coagulation Testsbusinessmedicine.drugEpirubicinThrombosis and Haemostasis
researchProduct

Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal ho…

1999

Abstract Objective: To compare compliance, symptom control, bleeding patterns, endometrial response, and lipid changes in postmenopausal women treated with transdermal E 2 and a regimen of either intermittent or continuous dosing of progestin. Design: Randomized, prospective study. Setting: Menopausal Outpatient Clinic at an academic tertiary care hospital. Patient(s): One hundred women who had reached menopause naturally and had been amenorrheic for at least 1 year. Fifty women were randomly assigned to receive each regimen. Intervention(s): All patients received 50-μg E 2 patches and medroxyprogesterone acetate, either 5 mg twice per week or 2.5 mg daily. The bleeding pattern was register…

medicine.medical_specialtymedicine.drug_classMedroxyprogesteroneMedroxyprogesterone AcetateAdministration CutaneousEndometriumInternal medicinemedicineMedroxyprogesterone acetateOutpatient clinicHumansProspective StudiesProspective cohort studyAgedmedicine.diagnostic_testEstradiolProgesterone Congenersbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyMiddle Agedmedicine.diseaseLipidsSurgeryMenstruationMenopauseRegimenReproductive MedicinePatient ComplianceFemaleProgestinsbusinessProgestinmedicine.drugEndometrial biopsyFertility and sterility
researchProduct

From structural biochemistry to expression profiling: Neuroprotective activities of estrogen

2005

Abstract Estrogens are neuromodulatory and neuroprotective hormones. Chemically, estrogens are steroid compounds and unfold most of their activities through the activation of nuclear receptors that bind to specific target genes and control their transcription. Two subtypes of estrogen receptors are known (estrogen receptor α and estrogen receptor β) and they are expressed throughout the body including the CNS and in particular the brain. We employed large scale DNA-chip-analysis to display the gene expression pattern differentially regulated by both estrogen receptor subtypes in human neuronal cells. We identified different gene families regulated by estrogen receptors that complement the k…

medicine.medical_specialtymedicine.drug_classModels NeurologicalEstrogen receptorBiologyNeuroprotectionAntioxidantsCell Line TumorInternal medicinemedicineHumansEstrogen receptor betaPELP-1EstradiolGene Expression ProfilingGeneral NeuroscienceBrainEstrogensCell biologyGene expression profilingNeuroprotective AgentsEndocrinologyReceptors EstrogenNuclear receptorEstrogenFemaleNervous System Diseaseshormones hormone substitutes and hormone antagonistsHormoneNeuroscience
researchProduct